Close Menu

People in the News

Mar 20, 2019

Ted Snelgrove

Liquid biopsy firm Lexent Bio has appointed Ted Snelgrove as its chief business officer. In the roll, Snelgrove will work closely with the CEO and  the company's board on test launch strategy, commercial team development, and corporate partnering.

Snelgrove's experience in molecular diagnostics includes building and leading the original commercial team for Genomic Health's Oncotype DX product line. He also built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, promoting the firm's Vectra DA for disease management in rheumatology. He was CEO at CellScape, an early player in the NIPT market, served as the oncology/hematology business unit head at Jazz Pharmaceuticals, and held C-Level roles at Counsyl and more recently at Guardant Health.

Mar 14, 2019

Michael Ball

Contextual Genomics has appointed Michael Ball as the firm's CEO. He previously served as global VP of commercial, informatics, at Illumina. Prior to Illumina, Ball acted as CEO of GenoLogics Life Sciences Software. He is currently a director of the Canary Foundation, a non-profit focused on early cancer detection.

Mar 12, 2019

Norman Sharpless

The US Health and Human Services Secretary Alex Azar has appointed Norman Sharpless as acting commissioner of the US Food and Drug Administration. Sharpless, currently the director of the National Cancer Institute, will take over for current FDA Commissioner Scott Gottlieb who announced on March 5 that he will resign from the post in one month. Before his position at the NCI, Sharpless directed the University of North Carolina's Lineberger Comprehensive Cancer Center, authored more than 100 research papers, and treated leukemia patients.

Mar 12, 2019

Patricia Rivera

Bioaffinity Technologies has formed a scientific and medical advisory board and named Patricia Rivera as the chairperson. Rivera is a professor of pulmonary diseases and critical care medicine at the University of North Carolina School of Medicine. She is also director of the UNC Lung Cancer Screening Clinic.

Mar 06, 2019

Todd Druley, Sandra Close, Karen Fritschen,

ArcherDx has appointed Todd Druley as the firm's chief medical officer, Sandra Close as the senior VP of regulatory and diagnostic strategy, and Karen Fritschen as VP of human resources.

Prior to joining ArcherDx, Druley most recently served as an associate professor of pediatrics, hematology, and oncology at Washington University of Medicine in St. Louis. He is an inductee into the American Society of Clinical Investigators and serves as a scientific advisor for Alex's Lemonade Stand Foundation, the Gateway Chapter of the Leukemia & Lymphoma Society, the Kids Shouldn't Have Cancer Foundation, the B+ Foundation, and the Eli Seth Matthews Leukemia Foundation. Druley will continue to see children with cancer predisposition as well as oversee his academic research lab at WUSTL.

Before joining ArcherDx, Close served as CEO of GenEngine. In addition she was responsible for building the health outcomes function for Baxter Healthcare/Caremark. She also lead the research and biomarker functions, including personalized medicine and companion diagnositics at Eli Lilly. Close also previously served as Arrogen's chief scientific officer.

Mar 05, 2019

Colin McCracken

Colin McCracken has joined Fluidigm as chief commercial officer. Prior to joining Fluidigm McCracken was vice president of chromatography and mass spectrometry, EMEA, for Thermo Fisher Scientific. He also previously led commecial operations in Europe for Invitrogen and Life Technologies, and has worked with Bristol-Myers Squibb.

Mar 04, 2019

Kathleen Sebelius

Exact Sciences has appointed Kathleen Sebelius to serve as a director on its board. She will sit on the firm's corporate governance and nominating committee and on its innovation, technology and pipeline committee. Sebelius currently serves as CEO of Sebelius Resources, a strategic consulting firm that advises private companies, non-profit organizations, and financial investors. From April 2009 through June 2014, she served as the Health and Human Services Secretary for President Barack Obama. She also served as Governor of Kansas from 2003 to 2009, and her previous elected offices include two terms as the Kansas insurance commissioner and four terms in the Kansas legislature.

Sebelius currently sits on the boards of biopharmaceutical companies Dermira and Myovant Sciences, as well as the Kaiser Family Foundation. She also co-chairs the Aspen Institute Health Strategy Group and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Estée Lauder Foundation, and the University of Kansas College of Liberal Arts and Sciences.

Feb 27, 2019

Todd Wood

DermTech has appointed Todd Wood as the firm's chief commercial officer. Wood brings 25 years of pharmaceutical and medical device commercialization experience to the firm. He has previously launch multiple market products, including Juvéderm, Limigan, and Rhofade.

Feb 26, 2019

Geoff Smith, Robert Nicol

DNA Script has formed a scientific advisory board, appointing Geoff Smith to serve as chair and Robert Nicol to serve as a second board member.

Smith is an expert in genomic technologies and their applications, having spent more than 10 years working as a vice president at Solexa/Illumina where he led the development of many aspects of the core SBS sequencing chemistry, workflows and platforms, and cell-free DNA pregnancy testing portfolio. After leaving Illumina, Smith served as CEO of Cambridge Epigenetix, and he now works as an advisor to a variety of companies in the genomics space.

Nicol serves as director of the technology labs at the Broad Institute. He is also the cofounder of the MIT-Broad Foundry for Synthetic Biology. Nicol joined the Whitehead Institute/MIT Center for Genome Research in 2001, and directed the sequencing operations and technology development groups at the Broad for more than 12 years.

Feb 26, 2019

Jack Crowley, Kavita Patel, Garry Nicholson

Personal Genome Diagnostics has appointed Jack Crowley as its chief financial officer. Crowley most recently served as CFO at Lantheus Medical Imaging, where he led a transition from a private equity-backed to a publicly-traded global life sciences company. Prior to serving as CFO, Crowley also served as Lantheus' chief accounting officer, VP of finance, and global corporate controller. He also served as director of finance and assistant corporate controller at Biogen and director of accounting at Thermo Fischer Scientific. A Certified Public Accountant, he holds an MBA from the University of Massachusetts and a BS in Business Administration from Westfield State University.

PGDx has also appointed Kavita Patel and Garry Nicholson to its board of directors. Patel has served in the Obama Administration as director of policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. Prior to the White House, she served as deputy staff director on health on the late Senator Edward Kennedy's staff. She also serves on the board of directors at Dignity Health and SSM Health Care. 

Nicholson currently serves as director at Five Prime Therapeutics, G1 Therapeutics, Tmunity Therapetics Inc, and SQZ Biotechnology. He previously served as President and CEO of XTuit Pharmaceuticals, as well as a member of the firm's board of directors. Prior to that, he served as president of Pfizer Oncology. He has also served on the Pfizer Foundation's board of directors and was a member of the firm's Portfolio, Strategy, and Investment Committee. In addition, Nicholson previously held leadership positions in the oncology division of Eli Lily. 

Feb 25, 2019

Laurie Heilmann

Laurie Heilmann has been appointed as senior vice president of business development and marketing at protein engineering company Codexis. Most recently, she was president of global life sciences and diagnostics, and before that, chief business officer and senior vice president of global strategy, business development, and marketing at Crown Bioscience.  

Feb 25, 2019

Don Elsey

OpGen has appointed Don Elsey to its board of directors and as the chairman of its audit committee. Elsey previously served as chief financial officer of Senseonics from 2015 to 2019. Prior to Senseonics, Elsey served as CFO of Regado Biosciences. He as also served as CFO of LifeCell and Emergent Biosolutions. In addition, Elsey has held senior financial positions at BioVeris, Igen, and PE (Applera). 

Feb 22, 2019

Jeffrey Alter, John Bigalke, Samuel Nussbaum, Lynne Powell

Progenity has appointed Jeffrey Alter, John Bigalke, Samuel Nussbaum, and Lynne Powell to its board of directors.

Alter is president of Arcturus One Consulting. He previously served as CEO of UnitedHealthcare's commercial group. Prior to that, he was senior VP of strategic financial planning for Oxford Health Plans. Before Oxford, he served as VP of finance, underwriting, and operations at Vytra Health Plans.

Bigalke is CEO of Second Half Healthcare Advisors. He is also chairman of VaxCares' advisory board and a member of Advent (formerly Adventist) Health System's advisory board. In addition, he is a senior advisor to Concord Management Services. Bigalke previously served as US national industry leader and senior partner for global healthcare and life sciences at Deloitte. Bigalke also was the firm's national director of public policy.

Nussbaum is a professor of clinical medicine at the Washington University School of Medicine. He is also a strategic consultant for EBG Advisors and a senior advisor to Sandbox Industries and the Ontario Teachers' Pension Plan. He serves on several boards, including those of Motus GI, Coherus Biosciences, and PhyMed. Prior to this, Nussbaum served as executive VP of clinical health policy and chief medical officer at Anthem. Previously, he was executive VP of medical affairs and system integration at BJC Healthcare. 

Powell serves as senior VP and chief commercial officer at BioCryst Pharmaceuticals. Prior to this, she was senior VP of North America at CSL Behring. Powell also served as the firm's VP of global commercial development and head of business development and European marketing. Prior to CSL, she held positions at Glaxo Wellcome's commercial strategy and clinical research organizations.

Feb 19, 2019

Anthony Schmidt

Circulogene has named Anthony Schmidt as the firm's medical director. He will lead the lab's precision medicine initiatives and educate the medical community about the firm's technologies. Schmidt was most recently pathology chair and lab medical director for the Mississippi Baptist Healthcare System.

Feb 19, 2019

Michael McGarrity

MDxHealth has appointed Michael McGarrity as its CEO and member of the firm's board of directors. Prior to MDxHealth, McGarrity served as CEO of Sterilis Medical. Previously, he was CEO of Nanosphere before it was acquired by Luminex in 2016. Prior to Nanosphere, McGarrity served in leadership roles at Stryker.

Feb 19, 2019

Andy Watson, Anthony Scarpello

Empire Genomics has appointed Andy Watson as CEO and Anthony Scarpello as chief commercialization officer. Watson was previously CEO at Genturi, a genomics technology startup. He was also chief commercial officer at RainDance Technologies, which was acquired by Bio-Rad Laboratories. Prior to Raindance, he was the vice president of SOLiD sequencing product management at Life Technologies, now part of Thermo Fisher Scientific. He also previously led the capillary electrophoresis sequencing business for Applied Biosystems, which became part of Life Technologies.

Scarpello was promoted from vice president of sales and business development to CCO. He joined Empire Genomics in 2009, and previously held numerous senior management roles with Enzo Life Sciences.

Feb 12, 2019

Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, Cameron Turtle

Caribou Biosciences has appointed Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, and Cameron Turtle to its scientific advisory board. 

Balskus is a professor of chemistry and chemical biology at Harvard University and an associate member of the Broad Institute of Harvard and MIT. Bhatt is an assistant professor of medicine (hematology) and genetics at Stanford University. Lee is a professor of pediatrics at Nationwide Children's Hospital and Ohio State University, and is also the founding director of the joint cellular therapy and cancer immunotherapy program between the Research Institute at Nationwide Children's Hospital and Ohio State University Comprehensive Cancer Center. Rathmell serves as director of the Vanderbilt Center for Immunobiology and as associate director of the Institute of Infection, Immunology and Inflammation at the Vanderbilt University Medical Center. Raje is a professor of Medicine at Harvard Medical School, director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. And Turtle is an associate member at Fred Hutchinson Cancer Research Center and an associate professor at the University of Washington.

The new members will join current scientific advisory board members and Caribou cofounders Jennifer Doudna and Martin Jinek.

Feb 08, 2019

David Anstey

Genomenon has appointed David Anstey as VP of sales and business department. Anstey previously served as VP of sales at Fabric Genomics. Prior to working at Fabric, Anstey held positions at Illumina, YarcData, and IDBS. 

Feb 08, 2019

Siddhartha Mukherjee

SEngine Precision Medicine has appointed Siddhartha Mukherjee to its advisory Board. Mukherjee is the Pulitzer Prize-winning author of the "The Emperor of All Maladies: A Biography of Cancer." Mukherjee is also an assistant professor of medicine and leading cancer researcher at Columbia University.

Feb 08, 2019

Martin Kunz

Twist Bioscience has appointed Martin Kunz as its senior VP of operations. Prior to Twist, he served as president of Eurofins Genomics US. Before serving as president, Kunz acted as chief technology officer at the firm. Prior to Eurofins, he served as chief information officer of Operon Biotechnologies. Kunz has also held a variety of positions at various companies in Switzerland. 

Feb 06, 2019

Susan Siegel

Illumina has named Susan Siegel to its board of directors. Siegel is chief innovation officer at General Electric and CEO of GE Ventures, which invests in startups and commercializes GE's intellectual property. Prior to joining GE, she was a general partner at Mohr Davidow Ventures, where she led investments in personalized medicine, digital health, and life sciences. Siegel was a founding representative member of the National Institutes of Health's National Center for Advancing Translational Sciences and also served on the Precision Medicine Initiative Working Group of the Advisory Committee to the NIH Director.

Feb 05, 2019

Gary Gregory

Perthera has appointed Gary Gregory as the firm's CEO, President, and board member. Gregory's 30 year experience spans several companies and positions, including executive officer roles across firms including Johnson & Johnson, Baxter, Kendal Healthcare, Neuronix, Advanced Dx, NeuroMetrix, and PrimeSource Healthcare. 

Jan 29, 2019

Jonathan Symonds, Sir John Chisholm, John Mattick, Mark Caulfield

Jonathan Symonds has been appointed as chair of Genomics England, replacing Sir John Chisholm, who stepped down this week. Symonds had been a senior non-executive director of the company since 2014.

In addition, John Mattick stepped down as CEO of Genomics England. He is temporarily replaced by Mark Caulfield, the company's chief scientist, who will serve as interim chief executive while a search for a permanent new CEO is ongoing.

Jan 25, 2019

John Steuart, Gail Marcus

John Steuart has resigned from Natera's board of directors. The board has also appointed Gail Marcus as chair of the audit committee. She joined Natera's board in March 2017 and currently serves as chair of the nominating and corporate governance committee.

Jan 25, 2019

Soren Germer, Michael Zody, Ana Bastiani-Posner

Soren Germer has been promoted to senior VP of genome technologies of the New York Genome Center. He previously served as the center's senior scientific director of sequencing operations, and before that, sequencing program manager. In his new role, Germer will lead the activities of the NYGC's sequencing and analysis teams.

Also, Michael Zody has been promoted to scientific director of computational biology of the NYGC, a new role. Zody will continue to provide scientific leadership to the computational biology team as well as lead new grants, foster partnerships, and serve as strategic scientific advisor.

In addition, Ana Bastiani-Posner has joined the NYGC as senior VP of finance and administration. Previously, she held executive finance roles at Allergan, Novartis Pharmaceuticals, and Schering-Plough.

Pages

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.